To listen to the webinar that accompanies this slide presentation, please visit: http://www.frost.com/prod/servlet/analyst-briefing-detail.pag?mode=open&sid=273389839
A watershed year in the history of healthcare, 2012 also marked the transition of emerging markets to the pinnacle of a sound, global growth strategy. In fact, aggregate emerging market revenues are expected to grow at a compound annual growth rate (CAGR) of approximately 15 percent from 2012 to 2016. Frost & Sullivan projects that emerging market revenues will match mature market revenues by 2020, with almost a 50 percent share between the two groups. With price and margin pressures, there is significant outsourcing of applications from R & D, manufacturing, clinical trials, and support functions to many of these emerging markets. To address this rapidly expanding growth opportunity, Frost & Sullivan launches the Growth, Innovation and Leadership (GIL) 100 Index as a structured means to identify, evaluate and prioritize a country pipeline system, which will ensure unrelenting growth over the next five years.